ReviewCurrent treatment options in cardiovascular medicine2019
Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations.
Review in Current treatment options in cardiovascular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.The New England journal of medicine · 2023 · on this mapTrial
- Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022 · on this mapTrial
- Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Early versus deferred antiretroviral therapy initiation and long-term cardiovascular disease outcomes in people with HIV: The START study.Open forum infectious diseases · 2025Article
- Diastolic Dysfunction with Vascular Deficits in HIV-1-Infected Female Humanized Mice Treated with Antiretroviral Drugs.International journal of molecular sciences · 2025Article
- Immunosenescence and its related comorbidities in older people living with HIV.Infectious diseases & immunity · 2025Review
- Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study.Mayo Clinic proceedings · 2022Article
- Ramadan fasting reduces high-sensitivity C-reactive protein among HIV-infected patients receiving antiretroviral therapy.Frontiers in nutrition · 2022Article
- Sex, HIV Status, and Measures of Cardiac Stress and Fibrosis in Uganda.Journal of the American Heart Association · 2021Article
- Brief Report: Vascular Dysfunction and Monocyte Activation Among Women With HIV.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Sex Differences in the Treatment of HIV.Current HIV/AIDS reports · 2020Review
- HIV and cardiovascular disease.The lancet. HIV · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is emerging as a major threat to healthy aging among people with HIV (PHIV). PHIV face heightened risks for coronary heart disease (CHD)/myocardial infarction (MI) and heart failure (HF), fueled by systemic immune activation and by metabolic dysregulation. Women with HIV (WHIV) evidence unique patterns of vascular and myocardial pathology as compared to men with HIV (MHIV). These patterns include a predilection to microvascular dysfunction and type II MI, as well as a penchant for diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF). Investigations are underway to understand how advanced reproductive aging among WHIV influences systemic immune activation and metabolic dysregulation en route to these CVD phenotypes. A key goal is to identify targeted CVD prevention strategies relevant to WHIV, particularly as efficacious treatment approaches to type II MI and HFpEF are lacking.
Indexed as
Identifiers
31309321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.